Kwon, Angela Eunyoung, Jaecheok Park, Gene Moo Lee. “Architectural Innovation, Organizational Restructuring, and the Role of AI: Evidence from the Rise of Antibody-Drug Conjugates,” Work-in-progress.

• Presentations: KrAIS (2026)

Architectural innovations reconfigure the linkages among existing components and thereby pose distinct challenges to established organizational structures. This study examines the rise of antibody-drug conjugates (ADCs) in oncology as a case of architectural innovation and investigates how this technological shift shapes organizational restructuring among pharmaceutical firms. Drawing on the theory of architectural innovation (Henderson & Clark,1990), we argue that ADCs disrupt established organizational routines and patterns of knowledge coordination, prompting firms engaged in oncology research to redesign internal roles, interfaces, and coordination mechanisms. We further theorize two moderators of firms’ adaptive effectiveness. First, AI capability functions as an architectural competence by facilitating cross-domain information processing and enabling knowledge recombination. Second, modality breadth provides absorptive capacity grounded in diverse drug development experience. This research-in-progress aims to contribute to the literature on architectural innovation and organizational restructuring by showing how firms adapt their internal structures to technological change, while also highlighting the emerging role of AI in firm-level knowledge coordination.